MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 20 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
Pertuzumab (Perjeta)
Reimbursement Team
2022· article· en· Canadian Journal of Health Technologies· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Trastuzumab Deruxtecan (Enhertu)
CADTH
2023· article· en· Canadian Journal of Health Technologies· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Trastuzumab Deruxtecan (Enhertu)
CADTH
2023· article· en· Canadian Journal of Health Technologies· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1
J. Cortés Castán, Sunil Verma, Sara A. Hurvitz, Ian E. Krop, Debu Tripathy, DA Yardley +5 more
2016· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
[Her-2/neu analysis--new data?].
Timo Gaiser, Michael Hofmann, Thomas Henkel, Josef Rüschoff
2006· article· en· PubMed· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
afffundunlabeled
Acute reactions to chemotherapy agents
Mário L de Lemos
2006· review· en· Journal of Oncology Pharmacy Practice· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Getting under the skin
Jean‐Michel Lavoie, Karen A. Gelmon
2017· letter· en· European Journal of Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About